Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation ( (JP:4883) ) has shared an announcement.
Modalis Therapeutics Corporation has completed the pay-in procedures for the issuance of 700 new common shares as part of a restricted-stock-based remuneration plan for its subsidiary employees. This move, resolved by the Board of Directors, aims to incentivize and retain key personnel, potentially strengthening the company’s operational capabilities and market position.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a biotechnology company listed on the Tokyo Stock Exchange, focusing on developing innovative therapeutics. The company is involved in the creation and commercialization of gene therapy solutions, targeting rare genetic disorders.
Average Trading Volume: 4,503,377
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.46B
For detailed information about 4883 stock, go to TipRanks’ Stock Analysis page.